Unlocking the power of the immune system against cancer and autoimmune disease.

A Global Leader in LAG-3 Immunotherapy for Cancer and Autoimmune Diseases

Immutep is a clinical-stage biotechnology company at the forefront of developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.

Our LAG-3 immunotherapies are distinctly designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease.

Latest press releases.

July 30th 2025

Immutep Quarterly Activities Report Q4 FY25
July 29th 2025

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer
July 28th 2025

Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
more

About us.

our science.

Utilizing our LAG-3 expertise, we’re focused on safely delivering on immunotherapy’s promise to drive superior clinical outcomes for patients.

our pipeline.

We have four clinical-stage assets & one earlier stage candidate, reflecting our unique ability to harness the LAG-3 immune checkpoint to stimulate or suppress the immune system.

investors & media.

We are dedicated to leveraging our technology to develop innovative treatment options for patients and to maximise value to shareholders. Learn more.